Aethlon's Hemopurifier Found Effective in Capturing Monkeypox Virus
Posted on: Friday, 9 May 2008, 06:00 CDT
Aethlon Medical has announced that researchers have completed in vitro studies, which verify the ability of the Aethlon Hemopurifier to effectively capture monkeypox virus.
In studies recently initiated by researchers, high concentrations of monkeypox virus (MPV) (approximately 35 thousand cpu/ml) were rapidly depleted from cell culture fluids when circulated through the Hemopurifier. The study data indicated that the Hemopurifier removed 46% of infectious MPV in the first hour of testing, 82% after six hours, and 98% after 20 hours. The studies were conducted in triplicate and data verification was provided by real-time polymerase chain reaction.
The MPV and vaccinia data further reinforces the use of the Hemopurifier as a broad-spectrum treatment candidate against bioterror threats, and will be included in a June 4, 2008 response to a government contract opportunity entitled 'application of platform technologies for the development of therapeutic agents for biodefense'. The data also documents the potential of the Hemopurifier to address specific smallpox treatment priorities that have been set forth by the US government.
Source: Datamonitor
Related Articles
- Verizon Business 2009 Data Breach Study Finds Significant Rise in Targeted Attacks, Organized Crime Involvement
- Cisco Data Leakage Study Assesses the 'Insider Threat'
- Teva Reports Positive Data From Study of Parkinson's Drug
- Verizon Business Releases Trailblazing Data-Breach Study Spanning 500 Forensic Investigations
- Data From Studies of Amrubicin in Small-Cell Lung Cancer Presented at the 2008 American Society of Clinical Oncology Meeting Demonstrate Single Agent Anti-Tumor Activity in Western Patient Population
- Promising Data ATIR Studies Presented By NIH Investigators
- IR BioSciences Announces Promising Data From Study of Its Compound Homspera
- Inotek Pharmaceuticals Announces Publication of Animal Data From Study of PARP Inhibition As Potential Preventative of Brain Injury Following Stroke
- Guidant Begins Enrollment in European Drug Eluting Stent Study; Data From Study Will Support Launch of XIENCE V Coronary Stent System Outside the United States
- Pharmacyclics Announces Presentation of Interim Data From Study Evaluating Xcytrin Plus Taxotere for Advanced Recurrent Tumors
 |
 |
User Comments (0)
RSS Feeds